Aflibercept biosimilar (Qilu Pharmaceutical)

阿柏西普生物类似药（齐鲁制药）

Report date: 2026/03/26 20:00:17

Base Information

Drug NameAflibercept biosimilar (Qilu Pharmaceutical)
Drug Alias Name重组人血管内皮生长因子受体-抗体融合蛋白注射液（齐鲁制药）卓初明QL-1207QL1207H
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsDiabetic macular oedemaMacular Degeneration
Approved Indications in ChinaDiabetic macular oedemaMacular Degeneration
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/13
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeL01XX44S01LA05
Related LinksN/A